Recludix Pharma

We are gearing up for the upcoming #BIOEurope conference, which is celebrating its 30th anniversary in Stockholm, Sweden from November 4-6. Reach out to meet us at the conference via: Matthew Caldemeyer or https://lnkd.in/eF56CSgp.??

Thank you, Andy Hsieh and the team at William Blair for inviting us to discuss our lead programs - oral inhibitors of STAT6 and STAT3 – and our drug discovery platform being deployed to successfully drug SH2 domains. Learn more: https://lnkd.in/eVmRp75Q

Our Head of R&D Ajay Nirula and Chief Business Officer Matthew Caldemeyer will be in Boston on September 25 at the BofA conference conducting one-on-one meetings. Reach out to connect: https://lnkd.in/eF56CSgp

At the Cantor Global Healthcare Conference in New York this week, our CEO Nancy Whiting and Head of R&D Ajay Nirula will be hosting meetings. We hope to see you there!

Our CEO Nancy Whiting will be at the Wells Fargo Healthcare Conference in Boston this Thursday. If you’re attending, contact us to connect: https://lnkd.in/eF56CSgp

Today, as we celebrate Women’s Equality Day, we reflect on the countless contributions made by women for humanity, for their community, to advance industry and knowledge, including in a field that we are particularly passionate about – health and science. To commemorate this day, our colleague Ksenya Cohen Katsenelson shared her inspiration to excel in a STEM career.

We are thrilled to have been selected as a Fierce 15 Biotech Company! As our President and CEO Nancy Whiting noted: "It truly has been a transformative time for Recludix. We are the first company to successfully drug SH2 domains, exciting targets that are critical in mediating protein-to-protein interactions in many diseases. Our innovative oral small molecule inhibitors are based on our proprietary platform, which integrates custom DNA-encoded libraries, parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. This cutting-edge platform led to a strategic collaboration with Sanofi to advance a novel oral STAT6 inhibitor in multiple immunological and inflammatory indications, which included a total of $125 million in near-term payments and more than $1.2 billion in potential future milestones, while having an option to participate in an equal profit-sharing arrangement in the U.S. Additionally, we have identified highly potent, selective and orally bioavailable STAT3 inhibitors in our wholly-owned STAT3 program. We are excited to advance these molecules towards the clinic, as STAT6 and STAT3 activation is found in multiple disease pathways.” Read about the recognition: https://lnkd.in/eXVdVv4z

If you are attending Oppenheimer’s Novel Targets in Immunology Summit in NY next week, you can catch our President and CEO Nancy Whiting participate in a panel entitled “Novel Immunological Mechanisms For Dermatological Disorders,” as well as both Nancy and our Head of R&D Ajay Nirula for one-on-one meetings. #OPCOImmunology

This #PRIDEMonth, we recognize the many accomplishments and contributions of the LGBTQIA+ community, and we also reflect on the right of being able to express yourself without prejudice. At Recludix, inclusion is essential, and diversity is power.

We’re excited to have data on our oral STAT3 small molecule inhibitors be featured in a plenary presentation today at the Society for Investigative Dermatology (SID) Annual Meeting. Read more: https://lnkd.in/gidksMyd